US2857313A - Self-lubricating granulation - Google Patents

Self-lubricating granulation Download PDF

Info

Publication number
US2857313A
US2857313A US574103A US57410356A US2857313A US 2857313 A US2857313 A US 2857313A US 574103 A US574103 A US 574103A US 57410356 A US57410356 A US 57410356A US 2857313 A US2857313 A US 2857313A
Authority
US
United States
Prior art keywords
granules
mixture
granulation
lubricating
lubricant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US574103A
Inventor
Cooper Jack
Pasquale Daniel Mario
Windheuser John Joseph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CIBA PHARM PROD Inc
CIBA PHARMACEUTICAL PRODUCTS Inc
Original Assignee
CIBA PHARM PROD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CIBA PHARM PROD Inc filed Critical CIBA PHARM PROD Inc
Priority to US574103A priority Critical patent/US2857313A/en
Priority to FR734770A priority patent/FR1215525A/en
Application granted granted Critical
Publication of US2857313A publication Critical patent/US2857313A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Definitions

  • wet granulation process In the manufacture of compressed tablets, two methods are generally used. The most common is the so-called wet granulation process. This is a long and tedious operation requiring many steps. It includes moistening a mixture consisting of the therapeutic component, excipients and binder with a suitable moistening agent, passing the wet mass through a screen to form granules, drying and rescreening the granules in order to reduce them to a size suitable for use in a tableting machine. At this point a lubricating agent is homogeneously admixed with the granulation in order to facilitate its passage through various orifices in the tableting machine.
  • slugging Another method for the preparation of compressed tablets is one commonly referred to as slugging. This method includes mixing the active ingredients with suitable excipients, compressing the dry powdered mass into large tablets or slugs, reducing the slugs to granules by forcing them through a screen of appropriate mesh size and recompressing the granules on a tableting machine.
  • the lubricant can be added in the initial mixing step but it is necessary to recompress the slugs after they have been granulated. It is also customary to add an additional lubricant before recompression to the final tablet shape.
  • the lubricant can be added to the initial powdered mixture and can be subjected to wet granulation.
  • An additional advantage in incorporating the lubricant in the initial pro-granulated mixture resides in the efficacy of the tableting operation. Where, as before, it was necessary to subject the granulation to an additional mixing step, thus reducing the control over the accuracy of dosage per unit and increasing the probability of error, contamination and loss, it is now possible to make tablets by a process which is more accurate, more efficient, and less time-consuming. Tablets prepared in accordance with our process do not vary in hardness, have optimal disintegration time, are smooth and readily extrudable by the machine. Pitting and jamming, because of lack of lubricant in the granulation, have not been observed.
  • Lubricants considered to be suitable in the operation of our process are talc, stearic acid, salts of this acid, preferably magnesium stearate and mixtures thereof.
  • the amount of lubricant in relation to the total weight of the tablet depends largely upon the nature of the lubricant employed, and for this reason may vary within certain prescribed limits. For example, if talcum is employed, it is preferable to use about 5% to 10% of the lubricant. If magnesium stearate is used, the limits are somewhat narrower in range, being from 0.5 to 2%. In the case of stearic acid one may use a quantity varying from about 2% to about 5%. If mixtures of these are used, the proportions will vary in accordance with the respective quantities employed.
  • Therapeutically active compounds which may be formulated in accordance with our improved method include tripelennamine, methyl-phenidylacetate, phenobarbital, aspirin, reserpine, glutethimide, hydrocortisone, cortisone and other substances usually administered in tablet form.
  • Excipients suitable for use in our process are milk sugar, corn starch or other therapeutically inert substances commonly employed for this purpose.
  • binders to insure adequate cohesive properties, may be used sucrose, gelatin, acacia or tragacanth.
  • a water-soluble polyethylene glycol such as Carbowax 6000 may be added to provide added binding properties.
  • Water, a lower alkanol such as methyl, ethyl, propyl or isopropyl alcohol, acetone, or mixtures thereof may be advantageously used as moistening agents in our process.
  • Example 1 100 grams of methyl phenidylacetate hydrochloride
  • Example 2 884 grams of lactose, 20 grams of tragacanth, 20 grams of acacia and 25 grams of talcum are mixed in a suitable container to a homogeneous mixture. 50 grams of polyethylene glycol 6000 are dissolved in'a solution containing 60 cc. of distilled water and 20 cc. of anhydrous 3A alcohol. The mixture of powders is granulated with the polyethylene glycol solution, passed through a No. 10 mesh screen, air-dried, passed through a No. 20 mesh screen and compressed into tablets.
  • Example 3 the steps of adding alubricating. agent, in: an: effective:
  • solvent containing a binding-lubricating agent,.said.agent having an effective amount of lubricant up to-and:includ-' ing about l0% by weight,,of the resulting,granu1es, and' forming the resulting mass into'granules;
  • a method for preparing granules of therapeutically active substances comprising the steps of moistening a dry, powdered mixtureof. a therapeutic agent, an excipient and an efiective amount up to and" including about 10%, by weight, of the resulting granules a member selected from the group consisting of talc, stearic acid, magnesium stearate and mixtures thereof with a solvent containing a binding agent, and forming the resulting mass'into granules.
  • a method for preparinggranules of therapeutically active substances comprising the steps of moistening a dry, powdered mixture of a therapeutic compound, an excipient and an effective amount upto' a'nd includingabout 10%, by Weight, of the resulting granules, a member selected fro mthe group consisting of talc, stearic acid, magnesium stearate and mixturesthereof withan aqueous solvent containing a'mernber of the group consisting ofsucrose, gelatin, acacia and tragacanth and forming the resulting mass intov granules.

Description

United States Patent 2,857,313 SELF-LUBRICATIN G GRANULATION Jack Cooper, Summit, Daniel Mario Pasquale, Livingston, and John Joseph Windheuser, Milton, N. J., assignors to Ciba Pharmaceutical Products, Inc., Summit, N. J., a corporation of New Jersey No Drawing. Application March 27, 1956 Serial No. 574,103
6 Claims. (Cl. 16782) This invention relates to a new and improved method for preparing tablet granulations.
In the manufacture of compressed tablets, two methods are generally used. The most common is the so-called wet granulation process. This is a long and tedious operation requiring many steps. It includes moistening a mixture consisting of the therapeutic component, excipients and binder with a suitable moistening agent, passing the wet mass through a screen to form granules, drying and rescreening the granules in order to reduce them to a size suitable for use in a tableting machine. At this point a lubricating agent is homogeneously admixed with the granulation in order to facilitate its passage through various orifices in the tableting machine.
Another method for the preparation of compressed tablets is one commonly referred to as slugging. This method includes mixing the active ingredients with suitable excipients, compressing the dry powdered mass into large tablets or slugs, reducing the slugs to granules by forcing them through a screen of appropriate mesh size and recompressing the granules on a tableting machine.
Thus, in the case of the wet granulation process, it has heretofore been thought necessary to include -in the wet mass only the drug, excipients and binder and to add the lubricant to the dried granulation in a separate step. If the slugging method is used, the lubricant can be added in the initial mixing step but it is necessary to recompress the slugs after they have been granulated. It is also customary to add an additional lubricant before recompression to the final tablet shape.
Contrary to the teachings of the art at the present time, we have found that the lubricant can be added to the initial powdered mixture and can be subjected to wet granulation. The incorporation of the lubricant in the initial mixture, as well as the wetting and drying of it, in no way detract from its lubricating properties. This is an unexpectedand surprising observation, inasmuch as it has been though that the dry free-flowing consistency of the lubricant can be retained only if its contact with .moistening agents is completely avoided. Our discovery that the lubricating properties of lubricants are not affected by moisture and drying, not only eliminates a step which heretofore has been considered essential in the preparation of tablet granulations, but affords a considerable saving in time in the overall tableting process.
An additional advantage in incorporating the lubricant in the initial pro-granulated mixture resides in the efficacy of the tableting operation. Where, as before, it was necessary to subject the granulation to an additional mixing step, thus reducing the control over the accuracy of dosage per unit and increasing the probability of error, contamination and loss, it is now possible to make tablets by a process which is more accurate, more efficient, and less time-consuming. Tablets prepared in accordance with our process do not vary in hardness, have optimal disintegration time, are smooth and readily extrudable by the machine. Pitting and jamming, because of lack of lubricant in the granulation, have not been observed.
2,857,313 Patented Oct. 21, 19 58 Lubricants considered to be suitable in the operation of our process are talc, stearic acid, salts of this acid, preferably magnesium stearate and mixtures thereof. The amount of lubricant in relation to the total weight of the tablet depends largely upon the nature of the lubricant employed, and for this reason may vary within certain prescribed limits. For example, if talcum is employed, it is preferable to use about 5% to 10% of the lubricant. If magnesium stearate is used, the limits are somewhat narrower in range, being from 0.5 to 2%. In the case of stearic acid one may use a quantity varying from about 2% to about 5%. If mixtures of these are used, the proportions will vary in accordance with the respective quantities employed.
The method we have described here may be advantageously applied to a wide variety of tableting formulae tions wherein the use of a lubricating agent is mandatory. Therapeutically active compounds which may be formulated in accordance with our improved method include tripelennamine, methyl-phenidylacetate, phenobarbital, aspirin, reserpine, glutethimide, hydrocortisone, cortisone and other substances usually administered in tablet form.
Excipients suitable for use in our process are milk sugar, corn starch or other therapeutically inert substances commonly employed for this purpose. As binders, to insure adequate cohesive properties, may be used sucrose, gelatin, acacia or tragacanth. If desired, a water-soluble polyethylene glycol such as Carbowax 6000 may be added to provide added binding properties. Water, a lower alkanol such as methyl, ethyl, propyl or isopropyl alcohol, acetone, or mixtures thereof may be advantageously used as moistening agents in our process.
The following examples are intended to illustrate this invention but are not intended to be limitative upon the scope thereof.
Example 1 100 grams of methyl phenidylacetate hydrochloride,
grams of confectioners sugar, 75 grams of talcum and 7.5 grams of magnesium stearate are mixed in a suitable container until homogeneous. 75 grams of polyethylene glycol 6000 are dissolved in 100 ml. water and the mixture is diluted with 100 ml. anhydrous 3A alcohol, heating, if necessary, to a temperature of about 45 C. to effect solution. The mixed powders are granulated with the polyethylene glycol solution, additional 50% 3A alcohol being added when necessary. The moist mass is pressed through a No. 10 sieve and is dried. The resultant granules are passed through a No. 16 mesh screen and compressed into tablets.
Example 2 884 grams of lactose, 20 grams of tragacanth, 20 grams of acacia and 25 grams of talcum are mixed in a suitable container to a homogeneous mixture. 50 grams of polyethylene glycol 6000 are dissolved in'a solution containing 60 cc. of distilled water and 20 cc. of anhydrous 3A alcohol. The mixture of powders is granulated with the polyethylene glycol solution, passed through a No. 10 mesh screen, air-dried, passed through a No. 20 mesh screen and compressed into tablets.
Example 3 the steps of adding alubricating. agent, in: an: effective:
amount up to and includingv about %,.by weight, of
the resulting granules to a dry, powdered mixture of. a. therapeutic compound and an-excipient, moistening said? mixture with a solvent containing a binding agent andv forming the resulting massinto granules.
2. In a method forv preparing granules of therapeutically active substances, the improvement which comprises the steps of adding a lubricating agent, in an efiective amount;
up to and including about 10%, by weight,.of. the. resulting granules to a dry, powderedimixture' of a therapeutic compound. and an excipient,. moistening said. mixture with a solvent containing a binding lubricating agent,
and forming theresulting mass into granules;
3. In a method for preparing granules ottlierapeutically active substances, the improvement which comprises the:
step of moistening a dry, powdered mixture'of. a'therapeutic compound and an excipient with a mixture'of. a
solvent containing a binding-lubricating agent,.said.agent having an effective amount of lubricant up to-and:includ-' ing about l0% by weight,,of the resulting,granu1es, and' forming the resulting mass into'granules;
4. In a method for preparing granules of therapeutically active substances, the improvement which comprises the:
steps of moistening a dry, powdered mixture of athera- A peutic compound, an excipient and a lubricating agent; in an. effective amount up to and including about 10%, by weight, of the resulting granules with a solvent containing a binding agent, and forming the resulting mass into granules.
5. In a method for preparing granules of therapeutically active substances, the improvement which comprises the steps of moistening a dry, powdered mixtureof. a therapeutic agent, an excipient and an efiective amount up to and" including about 10%, by weight, of the resulting granules a member selected from the group consisting of talc, stearic acid, magnesium stearate and mixtures thereof with a solvent containing a binding agent, and forming the resulting mass'into granules.
6. In a method for preparinggranules of therapeutically active substances, the improvement which comprises the steps of moistening a dry, powdered mixture of a therapeutic compound, an excipient and an effective amount upto' a'nd includingabout 10%, by Weight, of the resulting granules, a member selected fro mthe group consisting of talc, stearic acid, magnesium stearate and mixturesthereof withan aqueous solvent containing a'mernber of the group consisting ofsucrose, gelatin, acacia and tragacanth and forming the resulting mass intov granules.
References Cited in the file of this patent UNITED STATES PATENTS Kupferbert et al. Feb. 21, 1956

Claims (1)

1. IN A METHOD FOR PREPARING GRANULES OF THERAPEUTICALLY ACTIVE SUBSTANCES, THE IMPROVEMENT WHICH COMPRISES THE STEPS OF ADDING A LUBRICATING AGENT, IN AN EFFECTIVE AMOUNT UP TO AND INCLUDING ABOUT 10%, BY WEIGHT OF THE RESULTING GRANULES TO A DRY, POWDERED MIXTURE OF A THERAPEUTIC COMPOUND AND AN EXCIPIENT, MOISTENING SAID MIXTURE WITH A SOLVENT CONTAINING A BINDING AGENT AND FORMING THE RESULTING MASS INTO GRANULES.
US574103A 1956-03-27 1956-03-27 Self-lubricating granulation Expired - Lifetime US2857313A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US574103A US2857313A (en) 1956-03-27 1956-03-27 Self-lubricating granulation
FR734770A FR1215525A (en) 1956-03-27 1957-03-25 Process for preparing granulations for tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US574103A US2857313A (en) 1956-03-27 1956-03-27 Self-lubricating granulation

Publications (1)

Publication Number Publication Date
US2857313A true US2857313A (en) 1958-10-21

Family

ID=24294705

Family Applications (1)

Application Number Title Priority Date Filing Date
US574103A Expired - Lifetime US2857313A (en) 1956-03-27 1956-03-27 Self-lubricating granulation

Country Status (2)

Country Link
US (1) US2857313A (en)
FR (1) FR1215525A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3033754A (en) * 1959-12-21 1962-05-08 Lakeside Lab Inc Tablets containing hydrazine derivatives
US3039927A (en) * 1958-03-19 1962-06-19 Lafon Louis Pharmaceutical composition comprising aspirin and sorbitol
US3055433A (en) * 1957-08-28 1962-09-25 Ciba Ltd Epoxy-resin enteric coated tablet and composition
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US4254099A (en) * 1978-10-18 1981-03-03 Beiersdorf Aktiengesellschaft Pharmaceutical tablet composition
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20060281937A1 (en) * 2003-07-28 2006-12-14 Heider Todd P Stearate composition and method
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US20100183715A1 (en) * 2007-06-22 2010-07-22 Bristo-Meyers Squibb Company Tableted compositions containing atazanavir

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2115116C3 (en) * 1970-03-27 1982-04-15 Sankyo Co., Ltd., Tokyo Lubricants and process for their manufacture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735798A (en) * 1956-02-21 Acyl amevo-nitrothiazole compositions
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735798A (en) * 1956-02-21 Acyl amevo-nitrothiazole compositions
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055433A (en) * 1957-08-28 1962-09-25 Ciba Ltd Epoxy-resin enteric coated tablet and composition
US3039927A (en) * 1958-03-19 1962-06-19 Lafon Louis Pharmaceutical composition comprising aspirin and sorbitol
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3033754A (en) * 1959-12-21 1962-05-08 Lakeside Lab Inc Tablets containing hydrazine derivatives
US4254099A (en) * 1978-10-18 1981-03-03 Beiersdorf Aktiengesellschaft Pharmaceutical tablet composition
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US20050118257A1 (en) * 1993-09-20 2005-06-02 Bova David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US7998506B2 (en) 1993-09-20 2011-08-16 Kos Life Sciences, Inc. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20060281937A1 (en) * 2003-07-28 2006-12-14 Heider Todd P Stearate composition and method
US7385068B2 (en) 2003-07-28 2008-06-10 Mallinckrodt Inc. Stearate composition and method
US20100183715A1 (en) * 2007-06-22 2010-07-22 Bristo-Meyers Squibb Company Tableted compositions containing atazanavir
US20130266648A1 (en) * 2007-06-22 2013-10-10 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20150202191A1 (en) * 2007-06-22 2015-07-23 Bristol-Myers Squibb Company Tableted compositions containing atazanavir

Also Published As

Publication number Publication date
FR1215525A (en) 1960-04-19

Similar Documents

Publication Publication Date Title
US5635209A (en) Stabilized composition of levothyroxine sodium medication and method for its production
US2857313A (en) Self-lubricating granulation
EP0192173B1 (en) Direct tablet compressing aid
US3965256A (en) Slow release pharmaceutical compositions
US4235870A (en) Slow release pharmaceutical compositions
US5565442A (en) Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
US3773920A (en) Sustained release medicinal composition
US2540253A (en) Granulation process
US20090162429A1 (en) Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof
US2980589A (en) Process for producing anhydrous granulation of a medicinally active waterlabile powder
EP0275468B1 (en) Pharmaceutical compositions containing clodronate, and process for their preparation
KR940000232B1 (en) Process for preparing stable nicorandil preparation
EP1077681B1 (en) Pharmaceutical preparation containing levothyroxine sodium
US6761905B2 (en) Process for the preparation of direct tabletting formulations and aids
KR0177493B1 (en) Process for the preparation of a tablet containing a heat light and moisture sensitive active ingredient having monoclinic crystal structure
KR100580855B1 (en) Stabilized tibolone compositions
EP1094841B1 (en) Pharmaceutical levothyroxine preparation
US3175948A (en) Multivitamin tablets and premixes
KR0170380B1 (en) Stabilizing system for solid dosage forms
US3446899A (en) Vitamin compositions produced by direct compression
US3028307A (en) Pre-dried granulation and production of sublingual compressed organic nitrate tablets with selected solubilizing agents
JP2532224B2 (en) Nicorandil tablet manufacturing method
US3332848A (en) Microcrystalline cellulose with starch in niacinamide ascorbic acid tablet granulations
US3493659A (en) Compositions and process for the production thereof
US5520928A (en) Pharmaceutical composition of ticlopidine hydrochloride